<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00636935</url>
  </required_header>
  <id_info>
    <org_study_id>ARPCP001</org_study_id>
    <nct_id>NCT00636935</nct_id>
  </id_info>
  <brief_title>Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)</brief_title>
  <official_title>Oral Corticosteroids Therapy and Interstitial Fibrosis in Patients With Pneumocystis Jirovecii Pneumonia (PCP) and pO2 of &gt;70 at Presentation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the effects of corticosteroid therapy on pulmonary fibrosis and potentially
      pneumothorax in patients with mild PCP (pO2 &gt;70mmHg) combined with the standard of care
      treatment of antibiotic therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the development of highly active anti-retroviral therapy has substantially reduced
      the incidence of Pneumocystis jirovecii pneumonia (PCP) among HIV-infected individuals, PCP
      remains one of the most common presenting opportunistic infection among this population. The
      use of adjunctive corticosteroids in the treatment of patients with moderate to severe PCP
      has resulted in a significant improvement in the development of respiratory failure and
      mortality.

      Past studies have demonstrated no clinical benefit in patients with mild disease (pO2&gt;75 torr
      on room air). This may have been due to the fact that few patients with mild disease develop
      either respiratory failure or die during the course of the acute illness so that a
      statistical difference could not be demonstrated.

      However, considering parameters other than mortality, there is some evidence to suggest that
      patients with high pO2 concentrations benefit from adjunctive corticosteroids. PCP is
      associated with the development of pulmonary fibrosis and this can have significant
      consequences. Pathological studies have shown the development of interstitial fibrosis late
      in the course of acute illness. Studies have documented the presence of diffuse interstitial
      pneumonitis five months after the onset of acute illness. Therefore, patients with PCP
      infection, regardless of their pO2 level on presentation may benefit from corticosteroid
      therapy.

      The current standard of care therapy for patients with PCP does not involve the addition of
      corticosteroids to standard antibiotics in those patients with pO2&gt;70 mmHG. This study
      propose to conduct a randomized, prospective, un-blinded clinical trial to explore the
      effects of corticosteroid therapy on pulmonary fibrosis in patients with mild PCP who are
      admitted to the George Washington University Hospital.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patient completed protocol
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in pulmonary function testing and DLCO measurements in patients with PCP and pO2 &gt; 70 mmHg.</measure>
    <time_frame>1 month, 3 months and 6 months after diagnosis</time_frame>
    <description>Changes in pulmonary function testing and DLCO measurements in patients with PCP and pO2 &gt; 70 mmHg.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pneumocystis Carinii Pneumonia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antibiotic only therapy in patients with PCP and a pO2 of &gt; 70mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antibiotics and Corticosteroid therapy in patients with PCP and pO2 &gt;70 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care therapy for patients with PCP and pO2 &lt; 70mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics only</intervention_name>
    <description>Antibiotic only for treatment for mild (pO2 &gt; 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics + Corticosteroids</intervention_name>
    <description>Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Prednisone</other_name>
    <other_name>Bactrim</other_name>
    <other_name>Pentamidine</other_name>
    <other_name>Atovaquone</other_name>
    <other_name>Primaquine/Clindamycin</other_name>
    <other_name>Trimethoprim/Dapsone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids + antibiotics</intervention_name>
    <description>Drugs will be prescribed per standard of care for patients with PCP and pO2 &lt; 70mmHg.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Prednisone</other_name>
    <other_name>Bactrim</other_name>
    <other_name>Pentamidine</other_name>
    <other_name>Atovaquone</other_name>
    <other_name>Primaquine/Clindamycin</other_name>
    <other_name>Trimethoprim/Dapsone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV Infection,

          -  Hospital admission for suspected PCP,

          -  Confirmatory test for PCP (bronchoscopy with bronchoalveolar lavage), pO2&gt;70 mmHg or
             pO2&lt;70 mmHg while breathing room air,

          -  18 years or older

        Exclusion Criteria:

          -  Contraindications to corticosteroid therapy,

          -  Unable and or unwilling to perform PFTS or to return for follow-up evaluations,

          -  Underlying lung disease such as emphysema, untreated active tuberculosis, Uncontrolled
             diabetes (fasting glucose &gt; 250 mg/dL,

          -  Uncontrolled hypertension (160/95 mmHg),

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afsoon Roberts, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University Medical Faculty Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Associates</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, Bartok A, Niosi J, Abramson I, Coffman J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1990 Nov 22;323(21):1451-7.</citation>
    <PMID>2233917</PMID>
  </reference>
  <reference>
    <citation>Montaner JS, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990 Jul 1;113(1):14-20.</citation>
    <PMID>2190515</PMID>
  </reference>
  <reference>
    <citation>Nielsen TL, Eeftinck Schattenkerk JK, Jensen BN, Lundgren JD, Gerstoft J, van Steenwijk RP, Bentsen K, Frissen PH, Gaub J, Orholm M, et al. Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS: a randomized European multicenter open label study. J Acquir Immune Defic Syndr. 1992;5(7):726-31.</citation>
    <PMID>1613673</PMID>
  </reference>
  <reference>
    <citation>Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med. 1990 Nov 22;323(21):1444-50.</citation>
    <PMID>2233916</PMID>
  </reference>
  <reference>
    <citation>Gallant JE, Chaisson RE, Moore RD. The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Chest. 1998 Nov;114(5):1258-63.</citation>
    <PMID>9823998</PMID>
  </reference>
  <reference>
    <citation>Nowak J. Late pulmonary changes in the course of infection with Pneumocystis carinii. Acta Med Pol. 1966;7(1):23-41.</citation>
    <PMID>5296368</PMID>
  </reference>
  <reference>
    <citation>Whitcomb ME, Schwarz MI, Charles MA, Larson PH. Interstitial fibrosis after Pneumocystis carinii pneumonia. Ann Intern Med. 1970 Nov;73(5):761-5.</citation>
    <PMID>5312204</PMID>
  </reference>
  <reference>
    <citation>Sepkowitz KA, Telzak EE, Gold JW, Bernard EM, Blum S, Carrow M, Dickmeyer M, Armstrong D. Pneumothorax in AIDS. Ann Intern Med. 1991 Mar 15;114(6):455-9.</citation>
    <PMID>1994791</PMID>
  </reference>
  <reference>
    <citation>Coker RJ, Moss F, Peters B, McCarty M, Nieman R, Claydon E, Mitchell D, Harris JR. Pneumothorax in patients with AIDS. Respir Med. 1993 Jan;87(1):43-7.</citation>
    <PMID>8438099</PMID>
  </reference>
  <reference>
    <citation>Tumbarello M, Tacconelli E, Pirronti T, Cauda R, Ortona L. Pneumothorax in HIV-infected patients: role of Pneumocystis carinii pneumonia and pulmonary tuberculosis. Eur Respir J. 1997 Jun;10(6):1332-5.</citation>
    <PMID>9192938</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2008</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Gary Simon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pneumocystis jirovecii Pneumonia</keyword>
  <keyword>Corticosteroid Therapy</keyword>
  <keyword>HIV</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Pulmonary Function Testing</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>CD4</keyword>
  <keyword>CD8</keyword>
  <keyword>Viral Load</keyword>
  <keyword>Bactrim</keyword>
  <keyword>Pentamidine</keyword>
  <keyword>Atovaquone</keyword>
  <keyword>Primaquine/Clindamycin</keyword>
  <keyword>Trimethoprim/Dapsone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Dapsone</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Pentamidine</mesh_term>
    <mesh_term>Atovaquone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

